Literature DB >> 11502857

Autoimmune melanocyte destruction in vitiligo.

R van den Wijngaard1, A Wankowicz-Kalinska, S Pals, J Weening, P Das.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11502857     DOI： 10.1038/labinvest.3780318

Source DB:  PubMed          Journal:  Lab Invest        ISSN： 0023-6837            Impact factor:   5.662


× No keyword cloud information.
  14 in total

Review 1.  Hypopigmentary skin disorders: current treatment options and future directions.

Authors:  Anke Hartmann; Eva-B Bröcker; Jürgen C Becker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo.

Authors:  S Sanchez-Sosa; M Aguirre-Lombardo; G Jimenez-Brito; A Ruiz-Argüelles
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

Review 3.  Highlights in pathogenesis of vitiligo.

Authors:  Ghada F Mohammed; Amal Ha Gomaa; Mohammed Saleh Al-Dhubaibi
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

4.  Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.

Authors:  Jonathan M Eby; Hee-Kap Kang; Jared Klarquist; Shilpak Chatterjee; Jeffrey A Mosenson; Michael I Nishimura; Elizabeth Garrett-Mayer; B Jack Longley; Victor H Engelhard; Shikhar Mehrotra; I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2014-07-21       Impact factor: 4.693

5.  CTLA-4 A49G gene polymorphism is not associated with vitiligo in South Indian population.

Authors:  Farha Deeba; Rabbani Syed; Jariya Quareen; M A Waheed; Kaiser Jamil; Hanmanth Rao
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

6.  Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+/CD8+ T-cell ratio.

Authors:  Robert Pichler; Konstantin Sfetsos; Birgit Badics; Sabrina Gutenbrunner; Jörg Berg; Josef Auböck
Journal:  Wien Med Wochenschr       Date:  2009

7.  Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study.

Authors:  A Ruiz-Argüelles; M García-Carrasco; G Jimenez-Brito; S Sánchez-Sosa; B Pérez-Romano; J Garcés-Eisele; C Camacho-Alarcón; V Reyes-Núñez; M Sandoval-Cruz; C Mendoza-Pinto; A López-Colombo
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

8.  Original article title: "Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial".

Authors:  Reza Yaghoobi; Mohammad Omidian; Nooshin Bagherani
Journal:  BMC Dermatol       Date:  2011-03-31

9.  Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients.

Authors:  Suman Singh; Usha Singh; S S Pandey
Journal:  Indian J Dermatol       Date:  2012-01       Impact factor: 1.494

10.  Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy.

Authors:  Belinda Palermo; Silvia Garbelli; Stefania Mantovani; Claudia Giachino
Journal:  J Autoimmune Dis       Date:  2005-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.